Optimization of Meropenem Minimum Concentration/MIC Ratio To Suppress In Vitro Resistance of Pseudomonas aeruginosa
暂无分享,去创建一个
Vincent H. Tam | V. Tam | K. Poole | Elizabeth A. Coyle | A. Schilling | D. Melnick | Amy N. Schilling | Keith Poole | Shadi Neshat | David A. Melnick | S. Neshat
[1] W. Craig,et al. Killing and regrowth of bacteria in vitro: a review. , 1990, Scandinavian journal of infectious diseases. Supplementum.
[2] T. Köhler,et al. Carbapenem Activities against Pseudomonas aeruginosa: Respective Contributions of OprD and Efflux Systems , 1999, Antimicrobial Agents and Chemotherapy.
[3] M. Zhong,et al. Pharmacodynamic Assessment of Cefprozil againstStreptococcus pneumoniae: Implications for Breakpoint Determinations , 2000, Antimicrobial Agents and Chemotherapy.
[4] K. Poole,et al. Influence of Mutations in the mexR Repressor Gene on Expression of the MexA-MexB-OprM Multidrug Efflux System ofPseudomonas aeruginosa , 2000, Journal of bacteriology.
[5] Robert Leary,et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. , 2003, The Journal of clinical investigation.
[6] E. Bruck,et al. National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.
[7] G. Drusano,et al. The pharmacokinetics of meropenem. , 1995, Scandinavian journal of infectious diseases. Supplementum.
[8] R. Hancock,et al. Multidrug Efflux Systems Play an Important Role in the Invasiveness of Pseudomonas aeruginosa , 2002, The Journal of experimental medicine.
[9] J. Quinn,et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. , 2003, JAMA.
[10] N. Masuda,et al. Cross-resistance to meropenem, cephems, and quinolones in Pseudomonas aeruginosa , 1992, Antimicrobial Agents and Chemotherapy.
[11] Christina A. Sutherland,et al. Pharmacokinetics of Meropenem 0.5 and 2 g Every 8 Hours as a 3‐Hour Infusion , 2003, Pharmacotherapy.
[12] O. Cars,et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. , 2002, International journal of antimicrobial agents.
[13] S. Miyazaki,et al. Pharmacodynamics of S-3578, a Novel Cephem, in Murine Lung and Systemic Infection Models , 2004, Antimicrobial Agents and Chemotherapy.
[14] Michael Nikolaou,et al. Modelling time-kill studies to discern the pharmacodynamics of meropenem. , 2005, The Journal of antimicrobial chemotherapy.
[15] R. Owens,et al. Clinical pharmacodynamics of quinolones. , 2003, Infectious disease clinics of North America.
[16] N. Masuda,et al. Substrate Specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM Efflux Pumps in Pseudomonas aeruginosa , 2000, Antimicrobial Agents and Chemotherapy.
[17] Robert Leary,et al. Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa. , 2005, The Journal of infectious diseases.
[18] D. Livermore,et al. Beta-lactamase lability and inducer power of newer beta-lactam antibiotics in relation to their activity against beta-lactamase-inducibility mutants of Pseudomonas aeruginosa. , 1987, The Journal of infectious diseases.
[19] Max Salfinger,et al. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. , 2004, The Journal of infectious diseases.
[20] R. V. Miller,et al. Imipenem resistance in pseudomonas aeruginosa PAO: mapping of the OprD2 gene , 1991, Antimicrobial Agents and Chemotherapy.
[21] N. Masuda,et al. Outer membrane proteins responsible for multiple drug resistance in Pseudomonas aeruginosa , 1995, Antimicrobial agents and chemotherapy.
[22] J A Bilello,et al. Effect of 2',3'-didehydro-3'-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies , 1994, Antimicrobial Agents and Chemotherapy.
[23] D. Landman,et al. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. , 2002, Archives of internal medicine.
[24] K. Poole,et al. Differential Impact of MexB Mutations on Substrate Selectivity of the MexAB-OprM Multidrug Efflux Pump of Pseudomonas aeruginosa , 2004, Journal of bacteriology.
[25] Clinical,et al. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : Approved standard , 2006 .
[26] Mary Jane Ferraro,et al. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .
[27] T. Köhler,et al. In Vivo Emergence of Multidrug-Resistant Mutants ofPseudomonas aeruginosa Overexpressing the Active Efflux System MexA-MexB-OprM , 1999, Antimicrobial Agents and Chemotherapy.
[28] J. Bosso,et al. In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients , 1997, Antimicrobial agents and chemotherapy.
[29] V. Tam,et al. Pharmacodynamics of cefepime in patients with Gram-negative infections. , 2002, The Journal of antimicrobial chemotherapy.
[30] Angela Lee,et al. Identification and Characterization of Inhibitors of Multidrug Resistance Efflux Pumps in Pseudomonas aeruginosa: Novel Agents for Combination Therapy , 2001, Antimicrobial Agents and Chemotherapy.
[31] D. Nicolau,et al. Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. , 2003, The Journal of antimicrobial chemotherapy.
[32] W. Craig,et al. In Vivo Activities of Amoxicillin and Amoxicillin-Clavulanate against Streptococcus pneumoniae: Application to Breakpoint Determinations , 1998, Antimicrobial Agents and Chemotherapy.
[33] D. Livermore,et al. β-Lactamase Lability and Inducer Power of Newer β-Lactam Antibiotics in Relation to Their Activity Against β-Lactamase-Inducibility Mutants of Pseudomonas aeruginosa , 1987 .
[34] C. Wa,et al. Killing and regrowth of bacteria in vitro: a review. , 1990 .
[35] V. Tam,et al. Comparison of β-lactams in counter-selecting resistance of Pseudomonas aeruginosa , 2005 .
[36] V. Tam,et al. Novel Approach to Characterization of Combined Pharmacodynamic Effects of Antimicrobial Agents , 2004, Antimicrobial Agents and Chemotherapy.